44 results about "Hematopoietic stem cell" patented technology

The utility model provides a kind of hematopoietic stem cell liquid nitrogen transfer tank, it is related to the technical field of liquid nitrogen transfer tank.The hematopoietic stem cell liquid nitrogen transfer tank includes tank body, and the bottom surface of the tank body is fixedly connected with output port.The hematopoietic stem cell liquid nitrogen transfer tank is matched between output port, storage tank, gas outlet pipe and storage bag, when liquid nitrogen evaporates, the pressure in the tank body is increased, the moving plate will be moved downward, spring is compressed, telescopic rod is shortened, the moving plate will be separated from the screw pipe, gas enters the inside of storage tank, then enters storage bag through gas outlet pipe, nitrogen is stored, the pressure in the tank body is reduced, the problem that the liquid nitrogen transfer tank needs to be frequently opened and closed during use to take out or add hematopoietic stem cells is solved, a part of liquid nitrogen will evaporate and expand when tank cover is opened each time, if the gas cannot be effectively discharged, the pressure in the tank body may be sharply increased in a short time.

The present application relates to the technical field of biological medicine, and particularly relates to application of fullerenol in preparation of tumor prevention or treatment drugs for inducing trained immunity. The present application finds that fullerenol can induce formation of trained immunity, activate immune reprogramming of bone marrow hematopoietic stem cells, produce long-term pro-inflammatory phenotype, form persistent immune memory, and further enhance functions of innate immune cells. It is verified by experiments that fullerenol can significantly inhibit tumor growth in an animal model without obvious systemic toxicity; epigenetic remodeling of bone marrow hematopoietic stem cells can be sustained for several weeks to several months, and has long-acting anti-recurrence potential. In addition, trained immunity induced by fullerenol can be used for immune regulation of various solid tumors, and fullerenol is simple in synthesis, can be produced on a large scale, has excellent biocompatibility and stability. Therefore, the present application has wide application prospect.

The present invention relates to CD117 targeted LNP molecules for delivery of pro-apoptotic mRNA to hematopoietic stem cells (HSCs) and methods of use thereof for preconditioning a subject for hematopoietic stem cell therapy or to deplete the subject's HSC population for the treatment of a disease or disorder.

The present application relates to the use of idasanutlin, or a pharmaceutically acceptable salt, a solvate, an isomer, or a functional derivative thereof for the treatment of hemoglobinopathies, including sickle cell disease, thalassemia, sickle cell beta thalassemia (Hb S / β Th), and leukocytosis as well as myeloproliferative conditions, polycythemia, and acute and chronic hemolytic anemia. It was found that idasanutlin increases HbF levels in multipotent erythroleukemia, hematopoietic stem cells, and sickle cell disease cells to provide another therapy for treatment of sickle cell disease.

本发明公开了一种CD34+造血干细胞化学重编程为诱导多能干细胞的方法。所述方法包括：将CD34+造血干细胞分散为单细胞，接种于包被细胞外基质的培养表面，在无血清培养基中依次进行三阶段诱导培养：第一阶段培养基包含丙戊酸、CHIR99021、RepSox、EPZ6438、PY60、OAC1和OAC2；第二阶段培养基包含丙戊酸、CHIR99021、RepSox、反苯环丙胺、TTNPB、Forskolin、OAC1和OAC2；第三阶段培养基包含CHIR99021、Forskolin、Y‑27632、SP600125、OAC1和OAC2。最后挑取形成的iPSC克隆进行扩增培养，获得诱导多能干细胞。本发明针对CD34+造血干细胞优化了小分子组合和诱导时序，全程无病毒、无转录因子、无血清，重编程效率可达3%以上，细胞凋亡率低，可获得具有完整多能性和正常核型的iPSC，适用于临床级细胞制备和再生医学应用。

Described herein are compositions and methods for modifying eukaryotic cells, for example, to express a transgene of interest and / or to produce an expanded population of cells ex vivo. Using the compositions and methods of the disclosure, a population of eukaryotic cells, such as a population of pluripotent cells (e.g., CD34+ hematopoietic stem or progenitor cells) may be transduced to express a gene of interest by contacting the cells with a viral vector, such as a lentiviral vector, and a poloxamer. Additionally, the compositions and methods described herein can be used to promote the proliferation or survival of a population of pluripotent cells (e.g., CD34+ hematopoietic stem or progenitor cells) ex vivo, for example, by contacting the cells with a poloxamer. Examples of poloxamers that may be used in conjunction with the compositions and methods of the disclosure are those having a molar mass in excess of 10,000 g / mol, as well as those having a molar mass of polyoxypropylene subunits greater than 2,000 g / mol and / or an ethylene oxide content of greater than 40% by mass.

The application belongs to the field of cell biology, and provides a method for in-vitro differentiation and expansion of NK cells and application thereof, which comprises the following steps: (1) isolating umbilical cord hematopoietic stem cells; (2) culturing in a stem cell growth medium added with FLT3L, SCF, IL-7, IL-15 and IL-21 for 14 days; and (3) culturing in a stem cell growth medium added with FLT3L, SCF, IL-7, IL-15, IL-21 and BIX-01294 for 14 days. The method has good differentiation effect, and the obtained NK cells have good tumor killing effect.

The present invention provides compositions and methods for promoting the engraftment of exogenous hematopoietic stem cell grafts and for maintaining the pluripotency and hematopoietic function of these cells after transplantation. [Solution] The present invention provides compositions and methods useful for the depletion of cells such as CD45+, CD135+, CD34+, CD90+, and / or CD110+ cells, and, in particular, for the treatment of various hematopoietic disorders, metabolic disorders, cancer, and autoimmune diseases. For example, antibodies, their antigen-binding fragments, ligands, and conjugates that can be applied to achieve the treatment of these conditions by depleting populations of D45+, CD135+, CD34+, CD90+, or CD110+ cells in a patient such as a human are described herein.

The utility model belongs to the technical field of medical instrument cleaning, specifically a kind of hematopoietic stem cell culture dish cleaning device, including workbench and water inlet;The top of workbench is equipped with multiple circular grooves;Rotary rod is rotatably connected to the bottom of circular groove;The one end of rotary rod is equipped with power element;The outer circular wall of rotary rod is equipped with brush;The wall of circular groove is equipped with clamping element;The outer circular wall of water inlet is fixedly connected with multiple water spray pipes;One end of water spray pipe is connected to the bottom of circular groove;The top of workbench is fixedly connected with multiple limit rods;The outer circular wall of multiple limit rods is slidably connected with limit ring;The bottom of limit ring is fixedly connected with multiple discs;Disc is matched with circular groove;The sidewall of limit ring is threadedly connected with threaded rod;One end of threaded rod is rotatably connected to workbench;Multiple culture dishes can be cleaned in a short time, manpower is saved, and the work efficiency of researchers is improved.

The application provides application of a TADA2B gene in promoting terminal differentiation of erythroid cells, and relates to the technical field of biotechnology. The application comprises (I) promoting terminal differentiation of erythroid cells; (II) preparing a product for promoting terminal differentiation of erythroid cells; (III) promoting differentiation of hematopoietic stem cells into red blood cells; (IV) preparing a product for promoting differentiation of hematopoietic stem cells into red blood cells; and (V) preparing a drug for treating, preventing and / or alleviating a pathological condition or disease related to red blood cell deficiency of a subject. The application alleviates technical defects of existing in-vitro production of red blood cells.

Here, the inventors developed a strategy to modify the chromatin status of HSPCs at the HBG promoters to reactivate HbF expression. In particular, the inventors used from 1 to 4 single guide RNA (sgRNA) molecules spanning from the -220 to the -20 region of the HBG promoters together with CRISPR-based epigenome editors, namely dCas9-CBPcore and Tet1-dCas9. The first editor is capable of inserting histone acetylation while the second editor is performing DNA demethylation. Both epigenetic marks are associated with active transcription and are present in fetal erythroid cells expressing HbF. This strategy allows the ex vivo modification of adult HSCs to recreate a fetal-like epigenetic context leading to HbF production. Moreover, it avoids the genotoxicity associated with classical genome editing tools relying on DNA cleavage. Thus, the present invention relates to a method of increasing the expression of gamma globin in a population of eukaryotic cells through epigenome editing.

Methods to improve homing and engraftment of hematopoietic stem cells, particularly cord blood CD34+ cells, for use in hematopoietic cell transplantation through the regulation of expression of YTHDF2 or FTO in CD34+ cells. The methods include transiently repressing expression of YTHDF2 through exposure of the CD34+ cells to YTHDF2 repressor compound. The methods also include exposing CD34+ cells to a FTO expression activator compound to transiently increase FTO expression in the cells.

The present disclosure features methods and compositions for treating amyotrophic lateral sclerosis (ALS). The disclosed methods comprise administering to a subject having or suspected of having ALS a hematopoietic stem progenitor cell expressing at least one neuroprotective agent. The compositions disclosed comprise hematopoietic stem progenitor cells transduced to express a neuroprotective agent.

The present disclosure provides stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., T cells, B cells, natural killer cells, hematopoietic stem cells, to genetically modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.

The application discloses application of CREG1 protein in preparation of medicines or reagents for inhibiting hematopoietic stem cell aging, and belongs to the field of biological medicines. The application first finds that the CREG1 protein has the function of inhibiting hematopoietic stem cell aging (including inhibiting hematopoietic stem cell proliferation abnormality, maintaining hematopoietic stem cell resting state, reducing hematopoietic stem cell DNA damage, and weakening hematopoietic stem cell myeloid differentiation tendency). Therefore, the CREG1 protein has the prospect of being developed into the medicines or reagents for inhibiting hematopoietic stem cell aging, and also has the prospect of being developed into the medicines for improving the immune function decline, anemia, bone marrow hypofunction or blood system diseases caused by hematopoietic stem cell aging.

The present invention relates to a method for expanding hematopoietic stem cells and progenitor cells (HSPCs) for use in therapy.

Disclosed are methods and compositions for inhibiting endocytosis and enhancing function of hematopoietic stem cells. Certain aspects are directed to increasing MYCT1 activity or expression to improve hematopoietic stem cell self-renewal and / or engraftment ability.

The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and / or activities of target sequences. Provided are delivery systems and tissues or organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity and to edit or modify a target site in a genomic locus of interest to alter or improve the status of a disease or a condition.

This utility model relates to the technical field of liquid nitrogen storage devices, and in particular to a liquid nitrogen storage device for hematopoietic stem cells. It involves placing hematopoietic stem cells in a storage mechanism by activating a clamping mechanism, releasing liquid ammonia into the storage mechanism by activating a liquid supply mechanism, and allowing the liquid nitrogen to reach a designated position within the storage mechanism. When the hematopoietic stem cells need to be removed, they are retrieved using the clamping mechanism. A reheating mechanism is activated to release hot gas into the storage mechanism, reducing the reheating time and improving the device's usability. The device includes a clamping mechanism, a storage mechanism, a support mechanism, a liquid supply mechanism, an exhaust mechanism, and a reheating mechanism. The storage mechanism is located below the clamping mechanism, the support mechanism is located inside the storage mechanism, the liquid supply mechanism and the exhaust mechanism are both located on the right side of the storage mechanism, with the liquid supply mechanism in front of the exhaust mechanism, and the reheating mechanism on the left side of the storage mechanism.

The present invention relates to a method for producing hematopoietic stem cells derived from totipotent stem cells, and a method for producing a humanized mouse model using the produced hematopoietic stem cells. According to one aspect, the method for producing hematopoietic stem cells can highly efficiently differentiate hematopoietic stem cells from totipotent stem cells without gene insertion, and optimal differentiation conditions have been confirmed by combining low molecular weight compounds and protein growth factors.

The present disclosure provides distinct therapeutic populations of cells that form a pharmaceutical composition useful in hematopoietic stem / progenitor cell transplant. For example, the present disclosure provides a therapeutic population of cells, comprising an enriched population of hematopoietic stem / progenitor cells, memory T cells, regulatory T cells, and wherein the population of cells is depleted of naïve conventional αβ-T cells. The present disclosure further provides methods of treatment using the therapeutic population of cells. In other embodiments, the present disclosure provides methods of producing a therapeutic population of cells.

The present invention provides clinical evidence for a method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring myeloablative conditioning.

The application relates to the technical field of data processing, and particularly discloses a postoperative index analysis method for hematopoietic stem cell transplant patients based on machine learning, which is used for solving the problem that when hematopoietic stem cell transplant patients have high-dimensional coupling of subjective scales and objective indexes at T1, T2 and T3 multiple time points, and there are missing values, batch effects and individual differences, it is difficult to realize accurate evaluation of anxiety and depression when carrying out progressive muscle relaxation training combined with music therapy, and the method comprises the following steps: collecting postoperative indexes, building a matrix and preprocessing, splitting into A and B according to columns and calculating a difference, extracting U1, U2, V1 and V2 through four-dimensional branch lifting, and obtaining U, V and X by optimization, principal component projection is carried out on X to obtain the first K dimensions and threshold pruning to obtain W, and W and group time point interaction items are input into GLMM fitting to predict anxiety and depression; through four-branch dimension lifting fusion, principal component projection and threshold pruning, compact features are formed, and GLMM is combined to model, so that the accuracy of anxiety and depression evaluation and trend prediction is improved, and the interference of data missing and batch effect is reduced.

Provided herein are methods for expanding populations of hematopoietic stem cells (HSCs) or hematopoietic progenitor cells (HPCs) using extracellular vesicles isolated from hematopoietic stem cells (HSC-derived EVs) or from HPCs (HPC-derived EVs). Also provided are methods of using the isolated HSC-derived EVs and / or HPC-derived EVs as well as the HSCs and HPCs generated by or exposed to the methods disclosed herein.

The present application belongs to the technical field of cell separation, and particularly relates to a method for simultaneously separating hematopoietic stem cells and platelet-rich plasma from one portion of umbilical cord blood. The present application adopts two-step centrifugation to replace traditional multiple centrifugation separation, and has the advantages of simple operation, shortened time, reduced pollution risk, and the ability to simultaneously separate hematopoietic stem cells and platelet-rich plasma from one bag of umbilical cord blood, thereby avoiding waste of umbilical cord blood resources, and being particularly suitable for precious samples or clinical combined treatment.

This disclosure relates in part to lipid nanoparticles (LNPs) comprising a payload molecule (i.e., a nucleic acid molecule and / or a therapeutic agent), and methods of using thereto to deliver the payload molecule in vivo to target cells or target tissues. In some embodiments, the payload molecule comprises a peptide, a nucleic acid molecule, an enzyme, or any combination thereof. In some embodiments, the target cells are hematopoietic stem cells (HSCs). In some embodiments, this disclosure relates to the use of the lipid nanoparticles described herein for the treatment, prevention, and / or improvement of diseases and / or conditions in a subject, including but not limited to blood disorders.

The application belongs to the technical field of biological medicine, and particularly relates to application of a flavone small molecule compound in preparation of a drug for regulating WDR1 and / or treating leukemia. The flavone small molecule compound comprises Gambogic amide, Morellic acid, Flavopiridol hydrochloride, Gambogic Acid and / or Methylophiopogonanone B. The application research finds that the flavone small molecule compound such as Gambogic amide can effectively inhibit the activity of acute myeloid leukemia stem cells, and does not damage normal hematopoietic stem cells. The flavone small molecule compound is combined with WDR1 protein specifically expressed in the leukemia stem cells, induces cytoskeleton depolymerization, and further promotes the occurrence of leukemia stem cell apoptosis. The application provides a new direction for prevention and treatment of AML.